Abstract
Background : Percutaneous endoscopic gasrostomy (PEG) has been classified as a high bleeding risk procedure (ASGE and JSGE guidelies) . Patients who undergo PEG are often on antiplatelet therapy. Data on the safety of peri-procedual use of these drugs is limited.
Objective : To assess the risk of bleeding in paitents who receive antiplatelet therapy.
Method : PEGs were placed in 288 patients in our hospital from April 2008 to December 2011. 41 patients received antiplatelet therapy.
Results : In 41 patients who received antiplatelet therapy, 38 patients received mono antiplatelet therapy while 3 patients received dual antiplatelet therapy. 2 patients (4.9%) had evidence of bleeding after PEG and both received dual antiplatelet therapy (one was aspirin and clopidogrel, the other was cilostazol and clopidogrel) . There was no case of bleeding with mono antiplatelet therapy (0%) .
Conclusion : Use of single antiplatelet agent before or after PEG may not increase the risk of bleeding. Dual antiplatelet therapy should reduce to single agent.
